

PAR/CS/NSE/2026-27/02

Date: 14/05/2026

To,  
The Manager  
Listing department,  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block-G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai- 400 051  
Maharashtra


**Subject: Outcome of the Board Meeting held on Thursday, 14<sup>th</sup> day of May, 2026 in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015**

**Ref.: Symbol- PAR, ISIN: INE04LG01015**

Dear Sir/Madam,

The meeting of Board of Directors of the Company held on **Thursday, 14<sup>th</sup> day of May, 2026 at 3:30 P.M. at 333/1, G.I.D.C. Industrial Estate, Phase-II, Chitra, Bhavnagar – 364004** transacted the following businesses:

Item No.	Outcomes
1.	Pursuant to section 184(1) of the Companies Act, 2013, each director placed FORM MBP – 1 and board took note of respective particulars of each director about his/her concern or interest in any company or companies or bodies corporate, firms, or other association of individuals.
2.	Pursuant to section 164 (2) of the Companies Act, 2013, each director placed FORM DIR-8 and board took note that none of the directors are disqualified pursuant to section 164 (2).
3.	Board took note of declarations received under section 149(7) of the Companies act, 2013 from all the Independent Directors of the Company in compliance with section 149(6) of the Companies Act, 2013 & Regulation 16 (1)(b) of Securities And Exchange Board of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 and other requirement under respective act and regulation.
4.	<p>After the recommendation of Audit Committee, the Board of Directors considered, approved and took on record of Audited financial results for the quarter and year ended on March 31, 2026 along with statement of assets and liabilities, statement of profit &amp; loss and cash flow statement and Auditor's Report with unmodified opinion thereon, issued by CA Miral Mehta, Partner of Sarupria Somani &amp; Associates, Chartered Accountants, Statutory Auditor of the Company. The Board authorised Mr. Falgun V. Savani, Chairman and Managing Director (DIN: 00198236) and Mr. Jignesh Vallabhbbhai Savani, CEO &amp; Director (DIN: 00198203) to sign the approved financial results. The financial results were duly reviewed by Audit Committee at its meeting.</p> <p>Pursuant to Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Certificate of correctness was placed before the Board Meeting.</p> <p>Compliance Certificate pursuant to Regulation 17(8) read with Part B of Schedule II of SEBI (LODR) Regulations, 2015) is also submitted by the CEO and CFO of the Company</p> <p>Further, declaration is given by CFO of the Company pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.</p> <p>(The above documents are attached as Annexure 1,2,3 &amp;4 respectively.)</p>



5.	The Board considered and approved the drafts of advertisements to be published in newspapers regarding Audited Standalone Financial Results of the Company for quarter and year ended on 31 <sup>st</sup> March, 2026. The Board decided to publish the said advertisements in the Economic Times & Navgujarat Samay or as available.
6.	Board received, considered and approved Annual Audited financial statement with Audit Report for F.Y. 2025-26 ended on March 31, 2026 and authorised Mr. Falgun Savani (DIN: 00198236), Chairman & Managing Director; Mr. Jignesh Savani (DIN: 00198203), Director & CEO; Chief Financial Officer and Company Secretary of the company to sign the financial statements of the company including Balance Sheet as at March 31, 2026 and Statement of Profit and Loss for the year ended March 31, 2026 together with the notes and accounting policies attached thereto and Cash Flow Statements for the year ended on March 31, 2026 on behalf of the board and to submit the same to the Auditors of the company for their report thereon.
7.	After the recommendation of Audit Committee, Board received, considered and approved Internal Audit Report on the basis of internal audit conducted by M/s. SIDDHPURA & CO, Chartered Accountants for F.Y. 2025-26 ended on March 31, 2026.
8.	The Board took note of Investor grievances report for the quarter ended March 31, 2026 and reviewed the SCORES platform of SEBI to solve the investor compliant till date.
9.	The Board took note and review the Integrated Corporate Governance Report of the Company for the quarter ended March 31, 2026.
10.	Board received, considered and approved Human Resource Annual Report for the F.Y 2025-26 as presented by the HR head of the Company to the management and recommended to formulate strategies to foster a workforce-oriented approach in the year ahead.
11.	The Board took note of Actuarial valuation report as per AS 15 under the defined benefit scheme of Gratuity Benefits for the financial year ended March 31, 2026 received from Kapadia & Kochrekar Actuaries & Consultant of Mr. Saurabh Kochrekar, Fellow of Institute of Actuaries of India (ID: 19005)
12.	The board took note that the company has paid 10% of basic salary as a Bonus with total amount Rs. 25.14 lakh to the employees of the Company in the month of April 2026 for the F.Y. 2025-26
13.	By considering the suggestion of audit committee, the board has considered, discussed, approved and authorized Mr. Falgun V. Savani, Chairman and Managing Director (DIN: 00198236) and/or Mr. Jignesh V. Savani, Director & CEO (DIN: 00198203) of the Company to make investment as and when required in the liquid fund, arbitrage fund, fix deposit, etc up to the limit of ₹.90.00/- Crore approved by the board, which is within the limit defined under section 186 of the Companies Act, 2013.
14.	The Board considered and took note of renewal of Banking facility without any revision in the existing limit of Rs. 161.00 Lakh with Kotak Mahindra Bank, approved by the board and authorised Mr. Falgun V. Savani, Chairman and Managing Director (DIN: 00198236) and Mr. Jignesh Vallabhbhai Savani, CEO & Director (DIN: 00198203) to provide required resolution to the Bank and be and are hereby authorized to do sign/digitally sign all such necessary forms, documents, papers, and to do all such acts, matters, deeds as may be required for the above mentioned purpose.
15.	The Board considered and authorized Mr. Jignesh V. Savani, Director & CEO (DIN: 00198203) of the Company to file E-Form DPT-3 for the financial year ended on March 31, 2026, E-Form MGT-14 and other required Forms with the Registrar of Companies.
16.	The Board considered and authorized Mr. Jignesh V. Savani, Director & CEO (DIN: 00198203) of the Company to file FLA Return.
17.	The Board reviewed all policies of the Company as per the applicable act ,rules, regulations, etc. found proper by the Board
18.	Board reviewed terms and Conditions of appointment of Independent Directors found proper by the Board
19.	Board reviewed the code of conduct of the company found proper by the Board.
With the permission and consent of the Chairman and all the board of directors of the Company, following other matter were considered and approved	
20.	After the recommendation of Audit Committee, the Board of Directors has discussed, decided and approved to sale of Motor Vehicle of Company at total of Rs. 1.50 Lakh approx. Further, The Board authorised any of the current directors to sign and execute all such necessary forms, documents, agreement, papers, and to do all such acts, matters, deeds as may be required time to time for the sale of the motor vehicles.



**Although all the submission is made by integrated financial in XBRL format, this intimation shall also be considered as Integrated Filing (Financial) for quarter and year ended on 31<sup>st</sup> March, 2026 pursuant to Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 as follows:**

**QUARTERLY INTEGRATED FILING (FINANCIAL)  
FOR THE QUARTER ENDED MARCH 31, 2026**

PARTICULARS	DISCLOSURE
A. FINANCIAL RESULTS	Enclosed
B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.	<b>Not Applicable</b> <b>Reason of Non-Applicability:</b> As there is no any proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.
C. OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES	<b>Not Applicable</b> <b>Reason of Non-Applicability:</b> As there is no any outstanding default on loans and debt securities.
D. DISCLOSURE OF RELATED PARTY TRANSACTIONS	Submitted with Integrated Financial in XBRL format on the exchange
E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS	Auditor's Report with unmodified opinion thereon, issued by CA Miral Mehta, Partner of Sarupria Somani & Associates, Chartered Accountants.  Further, declaration given by CFO of the Company pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed herewith.  Further, the same is submitted with Integrated Financial in XBRL format on the exchange

Further, with reference to our intimation dated 26<sup>th</sup> March, 2026 and pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and amendment made time to time till date and according to Company's Code of Conduct to Regulate, Monitor and Report Trading by Insiders, the trading window for trading in securities of the Company will be opened after 48 hours of declaration of the attached financial result for Designated persons, Designated employees and their immediate relatives.

The Board Meeting was commenced at 3:30 PM and concluded at 6:16 PM.

Kindly take on the record and acknowledge the receipt.

Yours Faithfully,

**For PAR DRUGS AND CHEMICALS LIMITED**

(Sanket B. Trivedi)

Company Secretary & Compliance Officer

Encl: As above



**PAR DRUGS AND CHEMICALS LIMITED**

(CIN : L24117GJ1999PLC035512)

Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara-390007, Gujarat, India

Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com Website: www.pardrugs.com

Standalone Audited Financial Results for the Quarter and Year Ended 31st March, 2026

Standalone Balance Sheet as at 31st March, 2026

(Rs. In Lakhs)


Particulars	AS AT 31.03.2026	AS AT 31.03.2025
	Audited	Audited
<b>ASSETS</b>		
<b>(1) Non-Current Assets</b>		
(a) Property, Plant and Equipment	3,643.86	3,891.49
(b) Capital Work-in-Progress	71.70	0.00
(c) Investment in Property	0.00	0.00
(d) Goodwill	0.00	0.00
(e) Other Intangible Assets	0.00	0.00
(f) Intangible Assets Under Development	0.00	0.00
(g) Biological Assets Other Than Bearer Plant	0.00	0.00
(h) Financial Assets		
(i) Investments	2,713.64	2,507.00
(ii) Trade receivables	0.00	0.00
(iii) Loans	0.00	0.00
(i) Deferred Tax Assets (net)	0.00	0.00
(j) Other non-current assets	59.44	54.41
<b>Total Non-Current Assets</b>	<b>6,488.64</b>	<b>6,452.90</b>
<b>(2) Current Assets</b>		
(a) Inventories	537.28	610.59
(b) Financial Assets		
(i) Investments	0.00	0.00
(ii) Trade receivables	1,202.77	1,671.41
(iii) Cash and cash equivalents	4,184.29	2,757.72
(iv) Bank balances other than (iii) above	0.00	0.00
(v) Loans	11.12	9.90
(vi) other financial assets	0.00	0.00
(c) Current Tax Assets (Net)	474.76	424.36
(d) Other Current Assets	22.37	12.13
<b>Total Current Assets</b>	<b>6,432.59</b>	<b>5,486.11</b>
<b>TOTAL ASSETS</b>	<b>12,921.23</b>	<b>11,939.01</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share Capital	1,230.46	1,230.46
(b) Other Equity	9,968.00	8,667.03
<b>Total Equity</b>	<b>11,198.46</b>	<b>9,897.49</b>
<b>Liabilities</b>		
<b>(1) Non-Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	0.00	0.00
(ia) Lease Liabilities	0.00	0.00
(ii) Trade Payables:-		
(A) Total outstanding dues of micro and small enterprises; and	0.00	0.00
(B) Total outstanding dues of creditors other than micro and small enterprises	0.00	0.00
(iii) Other financial liabilities	0.00	0.00
(b) Provisions	24.01	26.66
(c) Deferred Tax Liabilities (Net)	324.40	358.00
(d) Other Non-Current Liabilities	0.00	0.00
<b>Total Non-Current Liabilities</b>	<b>348.41</b>	<b>384.66</b>
<b>(2) Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	0.00	0.00
(ia) Lease Liabilities	0.00	0.00
(ii) Trade Payables:-		
(A) Total outstanding dues of micro and small enterprises; and	80.06	34.49
(B) Total outstanding dues of creditors other than micro and small enterprises	739.33	1,054.65
(iii) Other financial liabilities	0.00	0.00
(b) Other Current Liabilities	95.90	109.75
(c) Provisions	459.07	457.97
(d) Current Tax Liabilities (Net)	0.00	0.00
<b>Total Current Liabilities</b>	<b>1,374.36</b>	<b>1,656.86</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>12,921.23</b>	<b>11,939.01</b>

For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited

Mr. Jigneshbhai V. Savani  
Director & CEO  
(DIN - 00198203)

For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited

Mr. Falgun V. Savani  
(Chairman & Managing Director)  
(DIN - 00198236)



**PAR DRUGS AND CHEMICALS LIMITED**  
(CIN : L24117GJ1999PLC035512)

Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara-390007, Gujarat, India  
Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com Website: www.pardrugs.com

Standalone Audited Financial Results for the Quarter and Year Ended 31st March, 2026

**Statement Of Profit & Loss**

(Rs. in Lakhs)

	Particulars	Quarter Ended			Year to Date	
		31-03-2026	31-12-2025	31-03-2025	31-03-2026	31-03-2025
		Audited	Unaudited	Audited	Audited	Audited
I	Revenue from operations	1,961.08	2,933.95	2,232.99	10,365.56	10,097.35
II	Other income	35.85	132.54	78.90	400.07	215.03
III	<b>Total Revenue (I + II)</b>	<b>1,996.93</b>	<b>3,066.49</b>	<b>2,311.89</b>	<b>10,765.63</b>	<b>10,312.38</b>
IV	<b>Expenses:</b>					
	Cost of materials consumed	884.59	1,211.91	1,043.47	4,267.05	3,940.86
	Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	6.26	27.48	-65.73	69.09	-127.83
	Employee benefits expense	193.54	141.01	191.01	612.01	585.18
	Finance costs	4.14	1.48	1.87	12.73	8.21
	Depreciation and amortization expense	92.75	93.13	92.03	370.33	364.66
	Other expenses	732.50	947.28	821.38	3,704.26	3,749.01
	<b>Total expenses (IV)</b>	<b>1,913.78</b>	<b>2,422.29</b>	<b>2,084.03</b>	<b>9,035.47</b>	<b>8,520.09</b>
V	<b>Profit / (loss) before exceptional items and tax (III-IV)</b>	<b>83.15</b>	<b>644.20</b>	<b>227.86</b>	<b>1,730.16</b>	<b>1,792.29</b>
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit / (loss) before tax (V - VI)</b>	<b>83.15</b>	<b>644.20</b>	<b>227.86</b>	<b>1,730.16</b>	<b>1,792.29</b>
VIII	<b>Tax expense:</b>					
	(1) Current tax	31.39	164.48	58.77	452.90	452.50
	(2) Deferred tax	-33.60	0.00	4.00	-33.60	4.00
IX	<b>Profit / (Loss) for the period from continuing operations (VII-VIII)</b>	<b>85.36</b>	<b>479.72</b>	<b>165.09</b>	<b>1,310.86</b>	<b>1,335.79</b>
X	Profit / (loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00
XI	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00
XII	<b>Profit / (loss) from Discontinued operations (after tax) (X-XI)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XIII	<b>Profit / (Loss) for the period (IX + XII)</b>	<b>85.36</b>	<b>479.72</b>	<b>165.09</b>	<b>1,310.86</b>	<b>1,335.79</b>
XIV	<b>Other Comprehensive Income</b>					
	A (i) items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	(ii) income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	B (i) items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	(ii) income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
XV	<b>Total Comprehensive Income for the period (comprising profit / (loss) and other comprehensive income for the period) (XIII + XIV)</b>	<b>85.36</b>	<b>479.72</b>	<b>165.09</b>	<b>1,310.86</b>	<b>1,335.79</b>
XVI		1,230.46	1,230.46	1,230.46	1,230.46	1,230.46
XVII	Paid up Equity share capital (Face value of Rs. 10 each)					
XVIII	Reserves & Surplus excluding revaluation reserve	9,968.00	9,882.75	8,667.03	9,968.00	8,667.03
	Earnings per equity share (for discontinued operation)					
	(1) Basic	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00
XIV	Earnings per equity share (for discontinued & continuing operation) (EPS for 3 and 9 months ended periods are not annualised)					
	(1) Basic	0.69	3.90	1.34	10.65	10.86
	(2) Diluted	0.69	3.90	1.34	10.65	10.86

For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited

Mr. Jigneshbhai V. Savani  
Director & CEO  
(DIN - 00198203)



For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited

Mr. Falgun V. Savani  
(Chairman & Managing Director)  
(DIN - 00198236)



PAR DRUGS AND CHEMICALS LIMITED  
(CIN : L24117GJ1999PLC035512)

Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara-390007, Gujarat, India  
Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com Website: www.pardrugs.com  
Standalone Audited Financial Results for the Quarter and Year Ended 31st March, 2026  
Statement of Cash Flow

Particulars	(Rs. In Lakhs)	
	Year Ended	Year Ended
	31.03.2026	31.03.2025
	Audited	Audited
<b>A: CASH FLOW FROM OPERATING ACTIVITIES:</b>		
Net profit before tax	1,730.16	1,792.29
<u>Adjusted for:</u>		
Depreciation	0.00	0.00
Income-tax/Prior Year Adjustment	370.33	364.66
Interest Expense	-9.88	-1.50
Rent, Interest & Dividend Income	0.00	0.00
Profit on Slump Sale of Ankleshar Unit	-183.83	-104.77
Profit/Loss on sale of assets	0.00	0.00
	-0.56	0.00
	176.06	258.39
<b>Operating Profit/(loss) before working capital changes</b>	<b>1,906.22</b>	<b>2,050.68</b>
<u>Adjustments for changes in working capital</u>		
<u>Adjustments for (increase)/decrease in operating assets</u>		
Loans & Other Non-Current Assets	-5.03	9.66
Inventories	73.31	-192.89
Trade Receivables	468.64	-299.99
Loans (Current Assets)	-1.22	+0.42
Other Current Assets	-10.25	16.00
<u>Adjustments for increase/(decrease) in operating liabilities</u>		
Provisions (Non-Current Liabilities)	0.00	0.00
Provisions (Current Liabilities)	-2.65	26.66
Other Current Liabilities	0.70	-11.41
Trade Payables	-13.85	-84.12
	-269.75	553.54
	239.90	17.03
<b>Cash Generated from / (used in) Operating activities</b>	<b>2,146.12</b>	<b>2,067.71</b>
Less: Income-Tax paid	-502.90	-451.68
<b>Net Cash generated from / (used in) Operating Activities:</b>	<b>1,643.22</b>	<b>1,616.03</b>
<b>B: CASH FLOW FROM INVESTING ACTIVITIES:</b>		
Purchase of Fixed Assets	-196.17	-122.66
Sales of Fixed Assets	2.34	0.00
Sale of Investment	-206.64	-2,505.81
Rent, Interest & Dividend Income	183.83	104.77
<b>Net Cash generated from / (used in) Investing Activities:</b>	<b>-216.64</b>	<b>-2,523.70</b>
<b>C: CASH FLOW FROM FINANCING ACTIVITIES:</b>		
Proceeds from Issue of Shares	0.00	0.00
Proceeds from Long Term Borrowings	0.00	0.00
Repayment of Long Term Borrowings	0.00	0.00
Repayment of Short Term Borrowings	0.00	0.00
Dividend Paid	0.00	0.00
Interest paid	0.00	0.00
<b>Net Cash generated from / (used in) Financing Activities:</b>	<b>0.00</b>	<b>0.00</b>
<b>Net Increase/(Decrease) in Cash and Cash Equivalents</b>	<b>1,426.58</b>	<b>-907.67</b>
<b>Opening Balance of Cash and Cash Equivalents</b>	<b>2,757.72</b>	<b>3,665.39</b>
<b>Closing Balance of Cash and Cash Equivalents</b>	<b>4,184.30</b>	<b>2,757.72</b>
<b>Total:</b>	<b>1,426.58</b>	<b>-907.67</b>

- Purchase of fixed assets are stated inclusive of movement of Capital Work in Progress and advance for capital goods between the commencement and end of the year/period and are considered as part of investing activity.
- The cash flow statement has been prepared under the "indirect method" as set out in the Ind-AS - 7 on Statement of Cash Flow as notified under the Companies (Accounts) Rules, 2014.

For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited

Mr. Jigneshbhai V. Savani  
Director & CEO  
(DIN - 00198203)



For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited

Mr. Falgun V. Savani  
(Chairman & Managing Director)  
(DIN - 00198236)



# **PAR DRUGS AND CHEMICALS LIMITED**

(CIN : L24117GJ1999PLC035512)

Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara (Gujarat)

Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com

Website: www.pardrugs.com

---

## **NOTES:**

1. The standalone financial results of the Company have been prepared in accordance with the Ind AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, other accounting principles generally accepted in India and in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, including relevant circulars issued by the SEBI from time to time.
2. The above quarterly and year to date financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14<sup>th</sup> May, 2026.
3. The Auditor of the company have carried out audit of the financial results for the quarter and year ended 31st March, 2026 in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015 and have expressed their unmodified opinion.
4. Figures for the quarter ended 31st March, 2026 are balancing figures between audited figures in respect of full financial year and the published year to date figures of the quarter ended 31<sup>st</sup> December, 2025. The figures up to the quarter ended 31st December, 2025 were subject to limited review.
5. The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earnings per share (not annualized) in accordance with the Ind AS.
6. Previous year / period figures have been regrouped / rearranged wherever necessary to make them comparable with current period figures.
7. The Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Ind AS - 108 on "Operating Segments". Accordingly, there are no separate reportable segments as per Ind AS - 108.



# **PAR DRUGS AND CHEMICALS LIMITED**

(CIN : L24117GJ1999PLC035512)

Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara (Gujarat)

Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com

Website: www.pardrugs.com

---

8. The Company does not have any subsidiary, associates or joint venture as on 31st March, 2026; therefore, it has prepared only standalone results as consolidation requirement is not applicable to the Company.

9. The above financial results of the Company are available on the Company's website – www.pardrugs.com and on the website of the National Stock Exchange of India Limited (www.nseindia.com), where the Company's shares are listed.

10. The Status of investors complaints are as follows:

I. Pending at the beginning of the quarter	-	0
II. Received during the quarter	-	4
III. Disposed-off during the quarter	-	4
IV. Remaining unresolved at the end of the quarter	-	0

For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited



Mr. Falgun V. Savani  
(Chairman & Managing Director)  
(DIN - 00198236)



For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited



Mr. Jigneshbhai V. Savani  
(Director & CEO)  
(DIN - 00198203)



Bhavnagar, 14<sup>th</sup> May, 2026



# Sarupria Somani & Associates Chartered Accountants

Partner : CA Miral Bipinbhai Mehta  
B.Com, FCA

CA Miral B. Mehta  
602, Victoria Corporate,  
Opp. Gulista Ground, Sony Show  
Room Lane, Vadodariya Park,  
Bhavnagar. Gujarat-364001  
Mobile : 9909366366  
Email : somanibvn@gmail.com

## INDEPENDENT AUDITOR'S REPORT

(Auditor's Report on Standalone Financial Results pursuant to Regulation 33 of the SEBI (Listing  
Obligation and Disclosure Requirements) Regulation, 2015)

TO  
THE BOARD OF DIRECTORS OF  
PAR DRUGS AND CHEMICALS LIMITED

### Report on the audit of the Standalone Financial Results

#### Opinion

We have audited the accompanying standalone quarterly financial results of **PAR DRUGS AND CHEMICALS LIMITED** (the company) for the **quarter ended 31<sup>st</sup> March, 2026** and the year-to-date results for the period from **1<sup>st</sup> April, 2025 to 31<sup>st</sup> March, 2026**, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("LODR Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the **net profit** and other comprehensive income and other financial information for the quarter ended **31<sup>st</sup> March, 2026** as well as the year-to-date results for the period from **1<sup>st</sup> April, 2025 to 31<sup>st</sup> March, 2026**.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these

## Branches

Udaipur • Ahmedabad • Akola • Mumbai • Delhi • Singruli • Jaipur • Gandhinagar  
Rudrapur • Indore • Pune • Kolkata • Ghaziabad • Raipur • Shimla • Chandigarh

**Key Audit Matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report.

**Assessment of Going Concern and Impact of Regulatory Proceedings on Strategic Restructuring****Why the matter was considered to be one of the most significant matters in the audit**

During the previous financial year, the Company had proposed a strategic restructuring plan involving the slump sale/business transfer of its primary business undertaking to a related party. The said undertaking constituted a substantial portion of the Company's revenue-generating and operational activities.

During the current financial year, the Securities and Exchange Board of India ("SEBI") issued an Ex-Parte Interim Order followed by a Confirmatory Order restraining the implementation of the proposed Business Transfer Arrangement ("BTA"). The Company is evaluating the available legal remedies, including the option of challenging the said orders before the appropriate appellate authority. Based on legal advice obtained and management's assessment of the matter, the management believes that it has adequate grounds to support its position.

Considering the significance of the proposed transaction, the ongoing regulatory proceedings, and the dependence of future business operations and funding plans on the outcome of such proceedings, significant management judgement and assumptions were involved in assessing the Company's ability to continue as a going concern. Accordingly, this matter was considered to be one of the most significant matters in our audit.

**How the matter was addressed in the audit**

Our audit procedures in relation to the above matter included, among others:

- Reviewing the Ex-Parte Interim Order and Confirmatory Order issued by SEBI and examining the related legal and regulatory correspondence made available to us;
- Discussing with management the current status of the proceedings and understanding the possible legal remedies available to the Company, including the proposed course of action before the appropriate appellate authority;
- Assessing management's evaluation of the impact of the regulatory proceedings on the proposed restructuring and on the future business operations of the Company;

- Reviewing management's cash flow forecasts, funding arrangements and key assumptions considered in assessing the appropriateness of the going concern basis of accounting;
- Considering legal opinions, representations and explanations provided by management in relation to the ongoing regulatory proceedings; and
- Evaluating the adequacy and appropriateness of disclosures made in the financial statements relating to the regulatory proceedings, uncertainties associated with the proposed transaction and the Company's going concern assessment.

Based on the audit procedures performed and the information and explanations provided to us, we found management's assessment of the going concern assumption to be reasonable and the related disclosures in the financial statements to be adequate and appropriate.

#### **Management's Responsibilities for the Standalone Financial Results**

These quarterly financial results as well as the year-to-date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

## **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

SARUPRIA SOMANI & ASSOCIATES  
(Firm Registration No – 010674C)  
CHARTERED ACCOUNTANTS



MIRAL MEHTA (Partner)

M.No.145361

Bhavnagar, 14<sup>th</sup> May, 2026

UDIN – 26145361ZYAAUO2067



To,  
The Board of Directors  
Par Drugs And Chemicals Limited

### CERTIFICATE OF CORRECTNESS OF FINANCIAL RESULTS

Pursuant to Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby certify that the financial results of the Company for the quarter and year ended on 31<sup>st</sup> March, 2026 placed before the meeting do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading.

For Par Drugs And Chemicals Limited

Date: 14/05/2026

Place: Bhavnagar



(Mr. Jignesh V. Savani)  
Chief Executive Officer



For Par Drugs And Chemicals Limited



(Mr. Chintan P. Chauhan)  
Chief Financial Officer



## COMPLIANCE CERTIFICATE

**(Pursuant to Regulation 17(8) read with Part B of Schedule II of SEBI (LODR) Regulations, 2015)**

To,  
**The Board of Directors**  
**Par Drugs And Chemicals Limited**

We, the undersigned, in our respective capacities as Chief Executive Officer and Chief Financial Officer of Par Drugs And Chemicals Limited ("the Company"), to the best of our knowledge and belief certify that:

- A. We have reviewed the financial statements and the cash flow statement for the year ended on 31<sup>st</sup> March, 2026 and based on our knowledge and belief, we state that:
1. These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
  2. These statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- B. We further state that to the best of our knowledge and belief, there are no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the Company's Code of Conduct.
- C. We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting and we have disclosed to the Auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.



D. We have indicated, based on our most recent evaluation, wherever applicable, to the Auditors and the Audit committee:

1. significant changes, if any, in internal control over financial reporting during the year;
2. significant changes, if any, in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
3. instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or any employee having significant role in the Company's internal control system over financial reporting.

**For Par Drugs And Chemicals Limited**

Date: 14/05/2026

Place: Bhavnagar




(Mr. Jignesh V. Savani)  
Chief Executive Officer



**For Par Drugs And Chemicals Limited**



(Mr. Chintan P. Chauhan)  
Chief Financial Officer



To,  
The Manager  
Listing department,  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block-G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai- 400 051  
Maharashtra

**Date:14-05-2026**

Subject: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015

**Symbol- PAR, ISIN: INE04LG01015**

Dear Sir/Madam,

I, **Chintan P. Chauhan, Chief Financial Officer** of Par Drugs And Chemicals Limited hereby declare that the Statutory Auditors of the Company, M/s Sarupria Somani & Associates, Chartered Accountants, having FRN 010674C, Partnership Firm, having peer review certificate, has submitted an Audit Report **with unmodified opinion** on Audited Standalone Financial Results of the Company for the financial year ended March 31, 2026.

This declaration is given pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Kindly take on the record and acknowledge the receipt

Yours Faithfully

**For PAR DRUGS AND CHEMICALS LIMITED**

  
\_\_\_\_\_  
**(Mr. Chintan P. Chauhan)**  
Chief Financial Officer

